Yeganeh Talebkhan

Yeganeh Talebkhan

Auto-generated profile, based on publicly available information

Yeganeh Talebkhan


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FNFatemeh Yadavar Nikravesh
Fatemeh Yadavar Nikravesh
SSSamira Shirkhani
Samira Shirkhani
EBElham Bayat
Elham Bayat
YTYeganeh Talebkhan
Yeganeh Talebkhan
EMEsmat Mirabzadeh
Esmat Mirabzadeh
SSSoroush Sardari
Soroush Sardari
Granulocyte colony stimulating factor (GCSF) can decrease mortality of patients undergo chemotherapy through increasing neutrophil counts. Many strategies have been developed to improve its blood circulating time. Albumin binding domain (ABD) was genetically fused to N-terminal end of GCSF encoding sequence and expressed as cytoplasmic inclusion bodies within Escherichia coli. Biological activity of ABD-GCSF protein was assessed by proliferation assay on NFS-60 cells. Physicochemical properties were analyzed through size exclusion chromatography, circular dichroism, intrinsic fluorescence spectroscopy and dynamic light scattering. Pharmacodynamics and pharmacokinetic properties were also investigated in a neutropenic rat model. CD and IFS spectra revealed that ABD fusion to GCSF did not significantly affect the secondary and tertiary structures of the molecule. DLS and SEC results indicated the absence of aggregation formation. EC50 value of the ABD-GCSF in proliferation of NFS-60 cells was 75.76 pg/ml after 72 h in comparison with control GCSF molecules (Filgrastim: 73.1 pg/ml and PEG-Filgrastim: 44.6 pg/ml). Animal studies of ABD-GCSF represented improved serum half-life (9.3 ± 0.7 h) and consequently reduced renal clearance (16.1 ± 1.4 ml/h.kg) in comparison with Filgrastim (1.7 ± 0.1 h). Enhanced neutrophils count following administration of ABD-GCSF was comparable with Filgrastim and weaker than PEG-Filgrastim treated rats. In vitro and in vivo results suggested the ABD fusion as a potential approach for improving GCSF properties.

28 October 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SMSomayeh Mazaheri
Somayeh Mazaheri
YTYeganeh Talebkhan
Yeganeh Talebkhan
FMFereidoun Mahboudi
Fereidoun Mahboudi
LNLeila Nematollahi
Leila Nematollahi
RCReza Ahangari Cohan
Reza Ahangari Cohan
FTFatemeh Torkashvand
Fatemeh Torkashvand
Certolizumab pegol is a Fab′ antibody fragment for treatment of rheumatoid arthritis and Crohn’s disease which is conjugated to a 40 kDa PEG molecule in order to increase the protein half-life. PEGylation may have disadvantages including immunogenicity, hypersensitivity, vacuolation, decreased binding affinity and biological activity of the protein. To overcome these problems, PASylation has been developed as a new approach. The nucleotide sequence encoding 400 amino acid PAS residues was genetically fused to the corresponding nucleotide sequences of both chains of certolizumab. Then, the bioactivity as well as physicochemical and pharmacokinetic properties of the recombinant PASylated expressed protein was assayed. Circular dichroism spectroscopy demonstrated that the random coil structure of PAS sequences did not change the secondary structure of the PASylated Fab′ molecule. It was observed that PASylation influenced the properties of the Fab′ molecule by which the hydrodynamic radius and neutralization activity were increased. Also, the antigen binding and binding kinetic parameters improved in comparison to the PEGylated Fab′ antibody. Pharmacokinetic studies also showed prolonged terminal half-life and improved pharmacokinetic parameters in PASylated recombinant protein in comparison to the PEGylated and Fab′ control molecules. The results reconfirmed the efficiency of PASylation approach as a potential alternative method in increasing the half-life of pharmaceutical proteins.

30 March 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SKSamira Komijani
Samira Komijani
EBElham Bayat
Elham Bayat
ERElham Rismani
Elham Rismani
SHSoma Hosseini
Soma Hosseini
RMReza Moazzami
Reza Moazzami
HJHoda Jahandar
Hoda Jahandar
Pseudomonas aeruginosa(PA) is a leading cause of nosocomial infections and death in cystic fibrosis patients. The study was conducted to evaluate the physicochemical structure, biological activity and serum stability of a recombinant anti-PcrV single chain variable antibody fragment genetically attached to the mCH3cc domain. The stereochemical properties of scFv-mCH3 (YFL001) and scFv (YFL002) proteins as well as molecular interactions towardsPseudomonas aeruginosaPcrV were evaluated computationally. The subcloned fragments encoding YFL001 and YFL002 in pET28a were expressed within theE. coliBL21-DE3 strain. After Ni–NTA affinity chromatography, the biological activity of the proteins in inhibition of PA induced hemolysis as well as cellular cytotoxicity was assessed. In silico analysis revealed the satisfactory stereochemical quality of the models as well as common residues in their interface with PcrV. The structural differences of proteins through circular dichroism spectroscopy were confirmed by NMR analysis. Both proteins indicated inhibition of ExoU positive PA strains in hemolysis of red blood cells compared to ExoU negative strains as well as cytotoxicity effect on lung epithelial cells. The ELISA test showed the longer serum stability of the YFL001 molecule than YFL002. The results were encouraging to further evaluation of these two scFv molecules in animal models.

30 March 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RDRada Dehghan
Rada Dehghan
APArezoo Beig Parikhani
Arezoo Beig Parikhani
SZSirous Zeinali
Sirous Zeinali
MSMohamadali Shokrgozar
Mohamadali Shokrgozar
AAAmir Amanzadeh
Amir Amanzadeh
MBMahdi Behdani
Mahdi Behdani
Interleukin-2 (IL-2) is an important cytokine in survival, expansion, function of CD8+ T cells and natural killer cells in immunotherapy of melanoma and renal cell carcinomas. Its severe toxicity following binding to its high affinity IL-2 receptor alpha (IL-2Rα) has restricted its application in cancer patients. In the present study, we investigated the antitumor efficacy and cytotoxicity of a mutated human IL-2 previously designed by selective amino acid substitutions, and its reduced affinity towards high-affinity IL-2Rα (CD25) was approved compared to the wild type IL-2 (wtIL-2). Furthermore, their ability to induce PBMC cell proliferation, and interferon-gamma secretion was compared. The mutant IL-2 also represented higher antitumor activity and more efficient cytotoxicity than wild type hIL-2. The developed mutant IL-2 can be an alternative tool in IL-2 associated immunotherapy of various cancers.

28 April 2019 in Preparative Biochemistry & Biotechnology
Verified
Journal Article
Closed access
FBFarzaneh Barkhordari
Farzaneh Barkhordari
NSNooshin Sohrabi
Nooshin Sohrabi
FDFatemeh Davami
Fatemeh Davami
FMFereidoun Mahboudi
Fereidoun Mahboudi
YGYeganeh Talebkhan Garoosi
Yeganeh Talebkhan Garoosi
In recent decades, immunotoxins have attracted significant attention in treatment of a wide range of diseases including cancers due to their natural origins and their role in blocking crucial pathways within the cells. Ribosome inactivating proteins (RIPs) are efficient molecules in blocking protein synthesis through interactions with ribosomal rRNA molecules. cDNA molecule encoding HER2 scFv antibody fragment originated from trastuzumab attached to the mature alpha luffin gene fragment was subcloned into pET28a expression vector and expressed in different E. coli expression hosts. Identity of the expressed recombinant protein was investigated through western blotting and the fusion protein was purified using Ni-NTA affinity chromatography. The biological activity (toxicity) of the protein was investigated on DNA and RNA samples. A 58 kDa protein was expressed in E. coli. The best protein expression level was achieved in 0.2 mM IPTG at 30 °C in TB medium using E. coli BL21 (DE3) host strain. The fusion protein showed RNase and DNA glycosylase activity on tested RNA and DNA samples. DNA glycosylase activity of the recombinant fusion protein showed that alpha luffin part of this protein is active in conjugation to the scFv molecule and the expressed protein can be further studied in targeted biological in vitro assays.

26 September 2020 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
NBNikta Babaee
Nikta Babaee
YGYeganeh Talebkhan Garoosi
Yeganeh Talebkhan Garoosi
MKMorteza Karimipoor
Morteza Karimipoor
FDFatemeh Davami
Fatemeh Davami
EBElham Bayat
Elham Bayat
FBFarzaneh Barkhordari
Farzaneh Barkhordari